Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Trastuzumab Combo Shows Numerical Survival Benefit in Gastric/GEJ Cancer
Telotristat Ethyl Plus Chemo May Stabilize Weight in Metastatic PDAC
Telephone Follow-Ups May Reduce AEs in Locally Advanced ESCC
Evorpacept Demonstrates Efficacy in HER2-Positive Gastric/GEJ Cancer